News Sentiment

BHVN sentiment intelligence

Biohaven Ltd. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 61 relevant articles
Exchange NYSE United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 15.55 Week of 10 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

79/100 classification confidence.

Company focus 53

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

-2.6% over one week, +37.9% over four weeks, trend active, and below fair value.

Latest direct headline Neutral

Price to earnings forward of Biohaven Ltd. – BOATS:BHVN

Market Reaction

Balanced read

60/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 79/100 classification
One-week reaction -2.6% Price reacting lower
Trend fit Trend active 37.9% over four weeks
Fair value -42.9% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 39
Negative 8

Relevance

Why the article matched

Direct first
Direct company coverage 53
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 10
Stock Titan 7
PR Newswire 7
TradingView 5
Moomoo 5
Sahm 3
Investing.com 2
simplywall.st 2

Event Lens

What the news is about

Classified themes
Market update 32
Earnings 17
Analyst action 7
Regulatory and legal 3
Deals and strategy 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 61
TradingView Direct company coverage

Price to earnings forward of Biohaven Ltd. – BOATS:BHVN

This page provides financial information for Biohaven Ltd. (BHVN), specifically focusing on its forward price-to-earnings ratio. It is hosted on TradingView, a platform offering market data, financial tools, and community features for traders and investors.

Tone
Neutral 50/100
Event
Earnings
Published
14 Jul 2026 19:13
Source
TradingView
TradingView Direct company coverage

Biohaven Research Ltd Shs Unsponsored Brazilian Depositary Receipt Repr 0.33333333 Shs

The article focuses on the "Price to book forward" for Biohaven Research Ltd Shs Unsponsored Brazilian Depositary Receipt Repr 0.33333333 Shs (BHVN34) traded on B3. It displays the stock's ticker, current market status, and various financial and technical data sections available

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 01:39
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Biohaven Ltd. – BOATS:BHVN

This article provides financial information for Biohaven Ltd. (BHVN), specifically its enterprise value to EBIT forward. It indicates various sections typically found on financial platforms, such as an overview, financials, news, and community features, but the core content only

Tone
Neutral 50/100
Event
Market update
Published
12 Jul 2026 18:39
Source
TradingView
Sahm Direct company coverage

Biohaven (BHVN) Advances Key Trials Following Pipeline Progress While Valuation Still Looks Pricey

Biohaven (BHVN) has reached two significant clinical milestones, completing enrollment for its RISE3 opakalim epilepsy trial and initiating Phase 3 testing for BHV-1300 in Graves' disease, leading to a recent surge in its stock price. Despite this positive momentum and a 51.4% 30

Tone
Neutral 50/100
Event
Market update
Published
11 Jul 2026 14:09
Source
Sahm
TradingView Direct company coverage

Enterprise value to revenue forward of Biohaven Ltd. – NYSE:BHVN

This article presents financial information focused on Biohaven Ltd. (NYSE: BHVN), specifically its enterprise value to revenue forward ratio. It appears to be a financial data snippet from TradingView, indicating no current trading activity as the market is closed.

Tone
Neutral 50/100
Event
Earnings
Published
11 Jul 2026 02:40
Source
TradingView
Moomoo Direct company coverage

Biohaven Chief Scientific Officer Bruce Car to Transition to Chief Innovation Officer

Biohaven Pharmaceutical Holding Company Ltd. announced that Bruce Car, Ph.D., will transition from Chief Scientific Officer to Chief Innovation Officer. In his new role, Dr. Car will focus on external pipeline innovation, business development, and strategic partnerships, while al

Tone
Positive 73/100
Event
Market update
Published
09 Jul 2026 23:39
Source
Moomoo
Stock Titan Direct company coverage

Janus Henderson holds 8.58M Biohaven shares (BHVN) — 5.7% stake

Janus Henderson Group Ltd. has filed an amended Schedule 13G/A, reporting beneficial ownership of 8,584,676 common shares in Biohaven Ltd. (BHVN), which constitutes a 5.7% stake as of June 30, 2026. The filing clarifies that Janus Henderson and its affiliated asset managers exerc

Tone
Neutral 50/100
Event
Deals and strategy
Published
09 Jul 2026 21:39
Source
Stock Titan
Investing.com Nigeria Direct company coverage

Biohaven announces leadership changes in discovery unit By Investing.com

Biohaven Ltd. has announced leadership changes within its scientific discovery unit. David Pirman has been promoted to Executive Vice President and Head of Discovery, while Bruce Car is transitioning from Chief Scientific Officer to a part-time Chief Innovation Officer role. The

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 21:39
Source
Investing.com Nigeria
PR Newswire Direct company coverage

Biohaven Announces Scientific Leadership Transitions

Biohaven Ltd. has announced scientific leadership transitions to accelerate drug innovation and external collaborations. David Pirman, Ph.D., has been promoted to Executive Vice President and Head of Discovery, leading internal drug-discovery. Bruce Car, Ph.D., is transitioning f

Tone
Positive 74/100
Event
Market update
Published
09 Jul 2026 21:12
Source
PR Newswire
Stock Titan Direct company coverage

Biohaven (NYSE: BHVN) shifts CSO to innovation role, promotes discovery head

Biohaven Ltd. (NYSE: BHVN) has announced significant scientific leadership changes. Bruce Car, Ph.D., will transition from Chief Scientific Officer to a part-time Chief Innovation Officer role, focusing on scientific initiatives and external collaborations, including those with B

Tone
Positive 67/100
Event
Market update
Published
09 Jul 2026 21:12
Source
Stock Titan
Moomoo Direct company coverage

Press Release: Biohaven Announces Scientific Leadership Transitions

Biohaven Pharmaceutical Holding Company Ltd. announced significant transitions in its scientific leadership. Dr. Stephen Hoffman, Chief Medical Officer, is retiring and will be succeeded by Dr. Richard Rodgers. Additionally, Dr. Vlad Coric has been appointed as the Chief Scientif

Tone
Positive 74/100
Event
Market update
Published
09 Jul 2026 20:39
Source
Moomoo
Market source Direct company coverage

Biohaven (BHVN) Completes Enrollment in RISE3 Trial

Biohaven (BHVN) has announced the completion of enrollment for its RISE3 trial, a pivotal Phase 2/3 study for opakalim in refractory focal epilepsy, with top-line results expected in the second half of 2026. The company also initiated a Phase 3 trial for BHV-1300 to treat Graves'

Tone
Positive 67/100
Event
Earnings
Published
09 Jul 2026 10:40
Source
Market source
Simply Wall Street Direct company coverage

Biohaven (BHVN) Is Up 5.6% After Advancing Two Late-Stage Trials in Epilepsy and Graves’ Disease

Biohaven (BHVN) has seen a 5.6% increase after advancing two late-stage trials: completing enrollment for its Phase 2/3 RISE3 trial of opakalim for refractory focal epilepsy and dosing the first patient in a Phase 3 trial of BHV-1300 for Graves’ disease. These milestones highligh

Tone
Positive 63/100
Event
Market update
Published
08 Jul 2026 21:39
Source
Simply Wall Street
Insider Monkey Direct company coverage

Why Wall Street Is Growing More Cautious on Biohaven (BHVN)

Wall Street is showing increased caution towards Biohaven (BHVN) due to mixed analyst sentiments. While BofA downgraded the stock and lowered its price target, citing concerns over its Kv7 epilepsy program and competitive landscape, Deutsche Bank raised its price target and maint

Tone
Neutral 50/100
Event
Analyst action
Published
06 Jul 2026 13:20
Source
Insider Monkey
Stock Traders Daily Direct company coverage

Discipline and Rules-Based Execution in BHVN Response

This article analyzes Biohaven Ltd. (NASDAQ: BHVN) using AI models to suggest trading strategies. It highlights strong near to mid-term sentiment but a weak long-term outlook, identifying compelling upside potential due to a lack of resistance levels above the current price. The

Tone
Positive 74/100
Event
Guidance
Published
06 Jul 2026 03:28
Source
Stock Traders Daily
Finviz Direct company coverage

BHVN - Biohaven Ltd Latest SEC Filings

This article provides the latest SEC filing details for Biohaven Ltd (BHVN), including its stock performance, key financial metrics, insider and institutional ownership, and valuation ratios. The company has a market cap of $2.40 billion and shows significant institutional owners

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 22:41
Source
Finviz
Intellectia AI Direct company coverage

Biohaven Shares Drop 9.8% to $14.28

Biohaven's shares fell 9.8% to $14.28, following a downgrade from BofA to Underperform with a reduced price target of $11, citing a bearish view on the risk-reward ahead of Phase 3 data for their kv7 epilepsy drug. This contrasts with a Deutsche Bank upgrade to a $20 price target

Tone
Neutral 50/100
Event
Analyst action
Published
03 Jul 2026 22:41
Source
Intellectia AI
Sahm Direct company coverage

Does Advancing Opakalim and BHV-1300 to Pivotal Trials Change The Bull Case For Biohaven (BHVN)?

Biohaven has advanced two key pipeline assets, opakalim for refractory focal epilepsy and BHV-1300 for Graves' disease, into pivotal trials, marking important milestones for the company's neurology and immunology pipeline. While this progress keeps the programs on track for poten

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 19:44
Source
Sahm
Sahm Direct company coverage

Analyst Warns Biohaven's Lead Drug May Struggle To Stand Out

Bank of America Securities downgraded Biohaven Ltd. to Underperform, lowering its price target to $11 from $12. The downgrade stems from concerns about Biohaven's lead epilepsy drug, Opakalim, which is expected to face significant competition from Xenon Pharmaceuticals' azetukaln

Tone
Neutral 50/100
Event
Analyst action
Published
30 Jun 2026 23:40
Source
Sahm
Stock Titan Direct company coverage

Biohaven's epilepsy drug Opakalim finishes pivotal study enrollment

Biohaven Ltd. (NYSE: BHVN) has completed enrollment in its pivotal Phase 2/3 RISE3 study for opakalim, a selective Kv7.2/7.3 activator, aimed at treating refractory focal epilepsy. Top-line results are anticipated in the second half of 2026. The company reported promising data fr

Tone
Positive 74/100
Event
Earnings
Published
30 Jun 2026 15:39
Source
Stock Titan
Investing.com Direct company coverage

Biohaven completes enrollment in opakalim epilepsy trial

Biohaven Ltd. has completed enrollment in its pivotal Phase 2/3 trial, RISE3, for opakalim, a treatment for refractory focal epilepsy, with top-line results expected in the second half of 2026. The company's stock has surged 32% in the past six months, reflecting optimism about i

Tone
Positive 65/100
Event
Earnings
Published
30 Jun 2026 12:10
Source
Investing.com
StreetInsider Direct company coverage

Biohaven completes enrollment in focal epilepsy drug trial

Biohaven Ltd. has completed enrollment in RISE3, a pivotal Phase 2/3 trial for opakalim, an investigational drug for refractory focal epilepsy. Top-line results for this study are anticipated in the second half of 2026. This development marks a significant step forward in the opa

Tone
Positive 73/100
Event
Regulatory and legal
Published
30 Jun 2026 11:10
Source
StreetInsider
Moomoo Direct company coverage

Update: BofA Securities Downgrades Biohaven to Underperform From Neutral, Trims Price Target to $11 From $12

BofA Securities has downgraded Biohaven Pharmaceuticals' rating from Neutral to Underperform. The firm also adjusted its price target for Biohaven, lowering it to $11 from $12. This revision reflects a more cautious outlook on the pharmaceutical company's future performance.

Tone
Negative 29/100
Event
Analyst action
Published
30 Jun 2026 11:09
Source
Moomoo